Bringing a new product to market requires more than scientific innovation, it demands the right expertise, the right timing, and the ability to adapt quickly to changing healthcare needs. Many small- to mid-sized biotech and pharmaceutical companies struggle with the cost and complexity of building full-scale Medical Affairs teams while trying to maintain speed, quality, and strategic focus. This is where experienced guidance becomes a critical advantage, helping organizations move from promising research to successful product launches with greater confidence and efficiency.
BioLogic Pharma Solutions is transforming the way biotech and pharmaceutical companies approach Medical Affairs and product launches. Through its flexible fractional consulting model, the company provides high-level strategic and clinical expertise without the burden of maintaining large full-time teams. Its experienced professionals support organizations across biotech, pharma, diagnostics, and rare disease sectors, combining deep scientific knowledge with practical leadership to solve complex challenges quickly and effectively.
The company offers tailored Medical Affairs consulting in strategic planning, KOL engagement, and trial recruitment, helping clients refine launch strategies, strengthen stakeholder relationships, and accelerate patient recruitment and study outcomes. By focusing on efficiency, scalability, and flexibility, BioLogic Pharma Solutions delivers cost-effective solutions that align with each client’s unique products, goals, and market opportunities.
Guided by a mission to make product launches faster, smarter, and more efficient, BioLogic Pharma Solutions also prioritizes growth through education, exceeding the customers’ expectations, and building the dream team. Through structured knowledge transfer and long-term partnership support, the company empowers clients to remain focused on advancing science while building a strong foundation for sustainable commercial success.
At CIO Bulletin, we had the distinct honor of interviewing Dr. Mary Hames, Founder and CEO of BioLogic Pharma Solutions. She shared compelling insights into how her team combines structured knowledge transfer with seamless scalability to create a resilient foundation for sustainable growth, empowering visionary science to take center stage and shape the future of healthcare.
In Conversation with Dr. Mary Hames
What inspired the founding of BioLogic Pharma Solutions, and what gap in the pharmaceutical and biotech ecosystem did you set out to address?
BioLogic Pharma Solutions was founded after I spent more than two decades working across pharmaceutical companies, biotechnology organizations, and diagnostic laboratories. Throughout those roles, I repeatedly saw promising therapies delayed by limited medical affairs resources, fragmented strategic planning, and a disconnect between scientific innovation and real-world execution. Smaller and emerging biotech companies often lacked access to experienced medical affairs leadership at the stage when it was needed most. I founded BioLogic to close that gap by providing flexible, senior-level expertise that integrates seamlessly with client teams, accelerates development, strengthens scientific strategy, improves clinical trial execution, and ultimately helps innovative therapies reach patients faster.
What are the primary services you offer, and what truly makes BioLogic stand out in a highly competitive, high-stakes market?
BioLogic Pharma Solutions provides strategic medical affairs consulting to pharmaceutical and biotechnology companies, with particular expertise in rare disease, neurology, and precision medicine. Our services include medical strategy, scientific communications, medical information, KOL engagement, clinical trial support, congress planning, publication development, field medical solutions, and diagnostic optimization. What differentiates BioLogic is our ability to function as an extension of our clients' teams rather than as an outside vendor. We combine deep scientific expertise with practical commercial experience, offering flexible, fractional medical affairs support that allows companies to access senior-level leadership without building large internal teams. Our focus on execution, responsiveness, and measurable outcomes enables clients to accelerate development, improve trial performance, and prepare confidently for successful product launches.
BioLogic offers a Fractional Medical Affairs model that provides expert support without the overhead of full-time teams. What makes your approach uniquely effective in accelerating and de-risking product launches?
Traditional medical affairs models often rely on a single full-time leader or require companies to build an entire department before it's truly needed. Our Fractional Medical Affairs model offers a smarter alternative. We assemble experienced, cross-functional experts who scale with a client's needs, providing immediate access to senior strategic and operational expertise without the cost and delay of building an internal team. Because our consultants have successfully supported multiple product launches across diverse therapeutic areas, they bring proven best practices, fresh perspectives, and the flexibility to rapidly address evolving priorities. This approach reduces key-person risk, accelerates critical activities such as KOL engagement, publications, investigator support, and launch planning, and enables emerging biopharma companies to execute with the capabilities of a much larger organization while remaining agile and cost-effective.
Key Opinion Leader (KOL) engagement and precise patient finding, especially in rare and monogenic diseases are extremely difficult. How does your contract medical affairs team optimize these areas to accelerate clinical trials and build market credibility?
Success in rare and monogenic diseases depends on reaching the right experts and the right patients early. Our contract medical affairs team develops tailored KOL engagement strategies that identify influential clinicians, researchers, advocacy leaders, and treatment centers capable of shaping clinical development and future adoption. We also implement innovative patient identification strategies, including diagnostic optimization, site education, referral pathways, genomic testing initiatives, and workflow tools that help clinicians recognize eligible patients sooner. Rather than relying on traditional outreach alone, we create practical, scalable solutions that improve trial awareness, increase screening efficiency, and strengthen investigator engagement. By combining scientific credibility with real-world execution, we help sponsors accelerate enrollment, generate meaningful clinical insights, establish trusted relationships with the medical community, and build a strong foundation for successful commercialization.
BioLogic places strong emphasis on efficiency, scalability, and flexibility. How do these principles shape the outcomes you deliver for emerging and established life sciences organizations?
Efficiency, scalability, and flexibility are central to every engagement because no two life sciences companies face the same challenges or timelines. We tailor our support to each client's stage of development, whether they need strategic guidance from a single senior expert or a fully integrated medical affairs team. Our scalable model allows organizations to rapidly expand or adjust resources as priorities evolve, avoiding the cost and complexity of building permanent infrastructure too early. This flexibility enables faster decision-making, more efficient execution, and better use of capital. For emerging biotech companies, it accelerates development while preserving runway. For established organizations, it provides specialized expertise that complements internal teams, increases capacity during critical milestones, and consistently delivers high-quality scientific and operational outcomes.
How does your team’s deep expertise across neurology, ophthalmology, radiopharmacology, and diagnostics translate into measurable advantages for your clients during critical pre-launch and launch phases?
Our therapeutic breadth allows us to bring insights that extend beyond a single indication or functional discipline. Experience across neurology, radiopharmaceuticals, and diagnostics enables us to anticipate challenges in clinical development, patient identification, evidence generation, and commercialization before they become barriers. We understand the unique scientific, regulatory, and operational complexities of each specialty while applying proven strategies across programs. This multidisciplinary perspective helps clients strengthen medical strategy, engage the right investigators and thought leaders, optimize diagnostic pathways, develop impactful scientific communications, and prepare field medical teams for launch. The result is faster execution, more informed decision-making, reduced development risk, stronger stakeholder confidence, and a more successful transition from clinical development to commercial readiness.
With your team scheduled to engage at high-profile clinical events like PMSF 2026, how does BioLogic leverage real-world medical congresses to bridge the gap between niche patient communities, researchers, and commercial success for your clients?
The Phelan-McDermid Syndrome Foundation (PMSF) Conference is much more than a scientific meeting—it is the largest gathering of families, clinicians, researchers, advocacy organizations, and industry partners dedicated to this rare disease community. For BioLogic, spending time with families is one of the most valuable aspects of the meeting. Hearing firsthand about their diagnostic journeys, daily challenges, treatment priorities, and hopes for future therapies provides insights that cannot be gained from published data alone. We help our clients translate these real-world perspectives into stronger medical strategies, more patient-centered clinical trial designs, meaningful educational initiatives, and authentic engagement with the community. By connecting scientific innovation with the lived experiences of patients and caregivers, we help clients build trust, strengthen development programs, and position future therapies for long-term success.
Looking ahead, what are your strategic priorities for growth? Are there any new services, capabilities, or initiatives in development that clients and industry partners should be particularly excited about?
Our strategic vision extends beyond transforming how medical affairs is delivered—we also see a fundamental shift occurring in who is driving drug development. Increasingly, patient advocacy organizations are becoming catalysts for therapeutic innovation by funding research, building patient registries, generating natural history data, and helping attract industry partners. BioLogic is proud to support this evolution by working alongside advocacy organizations to strengthen the scientific and operational foundations needed to advance potential therapies. We are helping these organizations develop trial-ready datasets, optimize diagnostic pathways, accelerate patient identification, and generate evidence that makes their communities more attractive to pharmaceutical partners. At the same time, we continue to expand our Fractional Medical Affairs model, replacing costly, siloed full-time positions with agile, multidisciplinary teams that deliver broader expertise, greater flexibility, and better economic value. Together, these initiatives position BioLogic at the intersection of scientific innovation, patient advocacy, and efficient drug development, helping to accelerate the journey from discovery to approved therapies.
As one of the “Best Companies to Watch 2026,” what legacy does BioLogic aim to build in the evolving landscape of medical affairs and biotech innovation?
Our goal is not simply to build a successful consulting company but to help redefine how medical affairs contributes to drug development. We want BioLogic to be recognized for demonstrating that agile, fractional teams can outperform traditional staffing models while making world-class expertise accessible to organizations of every size. We also hope to leave a lasting impact by helping accelerate therapies for rare and underserved diseases through deeper partnerships with patient advocacy organizations. As advocacy groups increasingly become drivers of research, natural history studies, patient registries, and therapeutic development, we are committed to serving as a bridge between patients, academia, and industry. If our legacy is that more patients receive life-changing therapies sooner because we helped connect them with the right people, generate the right evidence, and execute smarter medical strategies that will be our greatest measure of success.
The Visionary Leader Behind BioLogic Pharma Solutions’ Success
Dr. Mary Hames is the Founder and CEO of BioLogic Pharma Solutions, a women-owned strategic medical affairs consulting firm that serves pharmaceutical and biotechnology companies developing innovative therapies. A scientist, entrepreneur, business owner, and working mother, she brings more than 20 years of experience spanning diagnostics, medical affairs, clinical development, commercialization, and executive leadership. Throughout her career, she has supported programs across rare disease, neurology, precision medicine, and radiopharmaceuticals.
Dr. Hames is recognized for pioneering BioLogic’s Fractional Medical Affairs model, which provides companies with agile, multidisciplinary expertise that accelerates development while reducing costs and risk. She is equally passionate about advancing rare disease therapeutics through close collaboration with patient advocacy organizations, researchers, and industry partners, helping transform scientific discoveries into treatments that improve the lives of patients and families worldwide while inspiring the next generation of women leaders in science and business.
 consultants ltd.jpg)
